Use of a paracasei IOB413 probiotic and compositions thereof in gastric cancer

By combining Lactobacillus paracasei IOB413 as a postbiotic with folic acid, gastric cancer tumor growth is inhibited, solving the problem of significant side effects of existing treatments. This provides a safe, synergistic, and easily manufactured preoperative and postoperative treatment plan for gastric cancer, significantly inhibiting tumor progression and improving patient health.

CN120754141BActive Publication Date: 2026-07-03TIANJIN INNOORIGIN BIOLOGICAL TECH CO LTD
2 Cites 0 Cited by

Patent Information

Application Number
CN202511278005.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-09-09
Publication Date
2026-07-03
Estimated Expiration
2045-09-09

AI Technical Summary

Technical Problem

Existing drugs for treating gastric cancer, such as 5-fluorouracil, have significant adverse reactions, and there is a lack of clinical adjuvant therapies with minimal side effects before or after surgery, making it difficult to effectively inhibit the progression of gastric cancer and improve patients' health.

Method used

Using Lactobacillus paracasei IOB413 as a postbiotic and its combination with folic acid, a food-grade raw material and a mildly cultured probiotic preparation were prepared for the treatment of gastric cancer by inhibiting the epithelial-mesenchymal transition (EMT) process of tumor cells and regulating the IL-6/JAK2/STAT3 signaling pathway to block excessive activation.

Benefits of technology

It significantly inhibits gastric cancer tumor growth, reduces the invasive and metastatic potential of tumor cells, improves patients' gastrointestinal health, enhances preoperative tolerance and postoperative recovery, and provides a safe, synergistic, and easily manufactured treatment option.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention provides an application of *Lactobacillus paracasei* IOB413 metabiotic and its composition in gastric cancer, belonging to the field of microbial technology. *Lactobacillus paracasei* IOB413 has the preservation number CGMCC No. 16022. Its metabiotic can inhibit gastric cancer progression by suppressing epithelial-mesenchymal transition in tumor cells and regulating the IL-6 / JAK2 / STAT3 signaling pathway. The composition with folic acid has a synergistic effect, more effectively reducing tumor volume and lowering the levels of pro-inflammatory factors and tumor markers. It has high safety and is suitable as an adjuvant therapy before and after gastric cancer surgery, providing a new approach to gastric cancer treatment.
Need to check novelty before this filing date? Find Prior Art